Cardiovascular Outcome Studies with Glucagon-like Peptide 1 Receptor Agonists-what Will REWIND Add?

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2017 Dec 30

PMID 29285509

Citations 2

Authors

Keith C Ferdinand

Indrajeet Mahata

Affiliations

Soon will be listed here.

Citing Articles

Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force.

Kalra S, Das A, Sahay R, Baruah M, Tiwaskar M, Das S Diabetes Ther. 2019; 10(5):1645-1717.

PMID: 31359367 PMC: 6778554. DOI: 10.1007/s13300-019-0669-4.

Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment.

Brooks A, Langer J, Tervonen T, Peter Hemmingsen M, Eguchi K, Bacci E Diabetes Ther. 2019; 10(2):735-749.

PMID: 30847838 PMC: 6437254. DOI: 10.1007/s13300-019-0591-9.

References

Paneni F, Luscher T . Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. Am J Med. 2017; 130(6S):S18-S29. DOI: 10.1016/j.amjmed.2017.04.008. View

Scirica B, Bhatt D, Braunwald E, Steg P, Davidson J, Hirshberg B . Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14):1317-26. DOI: 10.1056/NEJMoa1307684. View

Marso S, Daniels G, Brown-Frandsen K, Kristensen P, Mann J, Nauck M . Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4):311-22. PMC: 4985288. DOI: 10.1056/NEJMoa1603827. View

Sokos G, Nikolaidis L, Mankad S, Elahi D, Shannon R . Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006; 12(9):694-9. DOI: 10.1016/j.cardfail.2006.08.211. View

Holman R, Bethel M, Mentz R, Thompson V, Lokhnygina Y, Buse J . Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(13):1228-1239. PMC: 9792409. DOI: 10.1056/NEJMoa1612917. View

de Denus S, OMeara E, Desai A, Claggett B, Lewis E, Leclair G . Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation. N Engl J Med. 2017; 376(17):1690-1692. PMC: 5590224. DOI: 10.1056/NEJMc1612601. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Ferdinand K, White W, Calhoun D, Lonn E, Sager P, Brunelle R . Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014; 64(4):731-7. DOI: 10.1161/HYPERTENSIONAHA.114.03062. View

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

10.

Tancredi M, Rosengren A, Svensson A, Kosiborod M, Pivodic A, Gudbjornsdottir S . Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med. 2015; 373(18):1720-32. DOI: 10.1056/NEJMoa1504347. View

11.

White W, Cannon C, Heller S, Nissen S, Bergenstal R, Bakris G . Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14):1327-35. DOI: 10.1056/NEJMoa1305889. View

12.

Lago R, Singh P, Nesto R . Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007; 370(9593):1129-36. DOI: 10.1016/S0140-6736(07)61514-1. View

13.

Green J, Bethel M, Armstrong P, Buse J, Engel S, Garg J . Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015; 373(3):232-42. DOI: 10.1056/NEJMoa1501352. View

14.

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

15.

Gerstein H, Colhoun H, Dagenais G, Diaz R, Lakshmanan M, Pais P . Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2017; 20(1):42-49. DOI: 10.1111/dom.13028. View

16.

Nissen S, Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356(24):2457-71. DOI: 10.1056/NEJMoa072761. View

17.

Benjamin E, Blaha M, Chiuve S, Cushman M, Das S, Deo R . Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017; 135(10):e146-e603. PMC: 5408160. DOI: 10.1161/CIR.0000000000000485. View

18.

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

19.

Pfeffer M, Claggett B, Diaz R, Dickstein K, Gerstein H, Kober L . Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015; 373(23):2247-57. DOI: 10.1056/NEJMoa1509225. View

20.

Ferdinand K, Botros F, Atisso C, Sager P . Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2016; 15:38. PMC: 4765050. DOI: 10.1186/s12933-016-0355-z. View